drugset / Trial / NCT07425392
Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The study will evaluate the safety, tolerability, and immunogenicity of VAX-31 in adults ≥50 years of age.
Timeline
- Start
- 2026-02-09
- Primary completion
- 2027-03
- Completion
- 2027-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | PCV20 | Vaccine | 0.5 ml | Intramuscular |
| Subject | VAX-31 | Vaccine | 0.5 ml | Intramuscular |
Indications
No indication recorded.